At present, the main targets of lung cancer targeted drugs that have been marketed and under development at home and abroad include epidermal growth factor receptor (EGFR) (HER1/ERBB1), HER2, MET, ROS1, VEGF, VEGFR2, and ALK5–10. This evidence concerns the gene EGFR and lung cancer.